Oncolytics Biotech Competitors and Similar CompaniesClear all
Oncolytics Biotech's competitors and similar companies include Ascentage Pharma, Achilles Therapeutics, Loxo Oncology and Epizyme.
 Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. |  Ascentage Pharma Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations. |  Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. | |
Founding Date | Founding Date 1998 | Founding Date 2017 | Founding Date 2016 | Founding Date 2013 | Founding Date 2007 |
Type | Type Public | Type Public | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Calgary, CA HQ Calgary, CA San Diego, US | Locations Suzhou, CN HQ Guangzhou Shi, CN Suzhou Shi, CN Taizhou, CN Rockville, US | Locations London, GB HQ Stevenage, GB | Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US | Locations Cambridge, US HQ |
Employees | Employees 28 | Employees 567 | Employees 695% decrease | Employees 65610% decrease | Employees 20364% increase |
Valuation ($) | Valuation ($) 93.9 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 250.8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥574.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $37.4m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods ¥48.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $10.5m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit ¥546.6m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($28.8m) (FY, 2025) | Net income (¥1.2b) (FY, 2025) | Net income ($69.7m) (FY, 2023) | Net income ($148.9m) (FY, 2017) | Net income ($251.1m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised $ 24m | Total funding raised $ 237.5m | Total funding raised $ 138.1m | Total funding raised $ 57m | Total funding raised $ 51.5m |
For sources of this data, please see the company profile
View Company Profiles
Ascentage Pharma
HQ
Suzhou, CN
Employees
567
Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyLoxo Oncology
HQ
Stamford, US
Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
View companyEpizyme
HQ
Cambridge, US
Employees
203
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
View company